Selected article for: "activity report and acute sars respiratory syndrome"

Author: Paragas, Jason; Blatt, Lawrence M.; Hartmann, Chris; Huggins, John W.; Endy, Tim P.
Title: Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models
  • Cord-id: o8ygdd14
  • Document date: 2005_2_15
  • ID: o8ygdd14
    Snippet: Preliminary data examining interferon alfacon1 treatment of SARS-CoV (severe acute respiratory syndrome-corona virus)-infected patients suggests this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon1, has potent in vitro antiviral activity against SARS-CoV. In a cytopathic effect protection (CPE) assay, interferon alfacon1 inhibited the generation of CPE in a dose-dependent manner with an IC(50) of 0.001 μg/ml, a clinically achievable level. Further
    Document: Preliminary data examining interferon alfacon1 treatment of SARS-CoV (severe acute respiratory syndrome-corona virus)-infected patients suggests this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon1, has potent in vitro antiviral activity against SARS-CoV. In a cytopathic effect protection (CPE) assay, interferon alfacon1 inhibited the generation of CPE in a dose-dependent manner with an IC(50) of 0.001 μg/ml, a clinically achievable level. Furthermore, interferon alfacon1 also demonstrated significant antiviral activity in yield reduction and plaque reduction assays. The in vitro antiviral activity of interferon alfacon1 against SARS-CoV suggests continued evaluation of interferon alfacon1 as a therapeutic treatment for patients infected with SARS-CoV.

    Search related documents:
    Co phrase search for related documents